SCHEMBL4409122

SCHEMBL4409122

O=C1NC[C@@H](C(=O)O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1291574 1.00
SCHEMBL6601988 1.00
SCHEMBL23227487 0.80
SCHEMBL27620693 0.80
SCHEMBL27881373 0.78 SMN1; SMN2 (0.41)
SCHEMBL4413281 0.78 SMN1; SMN2 (0.37)
SCHEMBL18306102 0.75 CHRNB2 (0.36)
SCHEMBL17585530 0.74
SCHEMBL5762322 0.72 RAB9A (0.54)
SCHEMBL3131226 0.72 HTT (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116056697-A 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors 默沙东有限责任公司 2023-05-02 CN disclosed
EP-4167994-A1 2-OXO-OXAZOLIDINE-5-CARBOXAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-26 EP disclosed
CN-109476653-B Heteroaromatic modulators of retinoid-related orphan receptor gamma 利奥制药有限公司 2022-04-22 CN disclosed
US-10934282-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma LEO PHARMA A/S (DK) 2021-03-02 US disclosed
US-20200291010-A1 HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA A/S 2020-09-17 US disclosed
EP-3484880-B1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA AS (DK) 2020-09-02 EP disclosed
US-10662181-B2 Heteroaromatic modulators of the retinoid-related orphan receptor gamma LEO PHARMA A/S (DK) 2020-05-26 US disclosed
US-10435403-B2 Positive allosteric modulators of muscarinic M2 receptor BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-10-08 US disclosed
US-20190284177-A1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA LEO PHARMA A/S (DK) 2019-09-19 US disclosed
EP-3484880-A1 HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA Leo Pharma A/S (DK) 2019-05-22 EP disclosed
EP-1660447-A1 CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORPORATION (US) 2006-05-31 EP disclosed
WO-2005082892-A2 TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LTD. (IN) 2005-09-09 WO disclosed
US-20050043290-A1 Cyclic amine BACE-1 inhibitors having a heterocyclic substituent SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. 2005-02-24 US disclosed
WO-2005014540-A1 CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT SCHERING CORPORATION (US) 2005-02-17 WO disclosed
EP-1019400-B1 BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORP (US) 2004-08-11 EP disclosed
EP-1019400-A1 BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2000-07-19 EP disclosed
US-5939416-A INHIBIT RAS FUNCTION, USE FOR TREATING TUMOR CELLS EXPRESSING AN ACTIVATED RAS ONCOGENE IN MAMMALS SCHERING CORPORATION (US) 1999-08-17 US disclosed
WO-1998057970-A1 BENZO(5,6)CYCLOHEPTAPYRIDINE COMPOUNDS USEFUL AS FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 1998-12-23 WO disclosed
US-5356918-A Oxazolidinone compounds and method of using the same as a vasodilator SANKYO COMPANY, LTD. (JP) 1994-10-18 US disclosed
US-5298516-A Treatment of cardiovascular disorders, angina SANKYO COMPANY, LIMITED (JP) 1994-03-29 US disclosed